steatohepatitis


Also found in: Medical, Wikipedia.
Related to steatohepatitis: fatty liver, cirrhosis, Alcoholic Steatohepatitis
Translations

steatohepatitis

n esteatohepatitis f; nonalcoholic — esteatohepatitis no alcohólica
References in periodicals archive ?
s (NYSE: CANF; TASE: CFBI) pre-clinical studies show Namodenoson's novel mechanism of action (MOA) entails de-regulation of 3 key signaling pathways that mediate the etiology and pathology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), and are responsible for the anti-inflammatory and anti-fibrogenic effect in the liver, the company said.
He sees limited read-through to nonalcoholic steatohepatitis, adding Intercept's "big multi-blockbuster opportunity is still intact.
The end result was non-alcoholic steatohepatitis (Nash) - a dangerous inflammatory condition that can lead to cirrhosis and liver cancer.
A clinical-stage Biopharmaceutical company, Galmed Pharmaceuticals, is focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases.
Promethera hopes the provide a platform to expand the manufacturing capabilities for its liver-derived cell therapies targeting non-alcoholic steatohepatitis (NASH), acute-on-chronic liver-failure (ACLF), and other indications.
NeuroVive Pharmaceutical AB, the mitochondrial medicine company, today announced that an abstract with new preclinical data related to the companys project NVP022 for non-alcoholic steatohepatitis (NASH) has been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington DC, October 20-24, 2017.
com)-- Non-alcoholic Steatohepatitis or Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis).
If fat in your liver causes the liver to swell then it is called steatohepatitis i.
A multimodal research process has provided clues to the role of angiogenesis in the etiology of nonalcoholic fatty liver disease (NAFLD) and its more serious cousin, nonalcoholic steatohepatitis (NASH).
Long-term pioglitazone is not only safe for patients with non-alcoholic steatohepatitis and prediabetes or type 2 diabetes but may be associated with significant improvements in fatty liver disease outcomes, compared with placebo, a study showed.
2) The spectrum of NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASFI) to cirrhosis.
GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015" provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario.